Chris Neal, CEO of MD Hyperbaric, expressed his enthusiasm for the partnership: “This collaboration with DataBiologics marks a pivotal moment in hyperbaric medicine. By leveraging their cutting-edge platform, we're not just collecting data; we're unlocking the full potential of HBOT. This partnership will enable us to quantify the real-world impact of our treatments and deliver more targeted, effective care to our patients. It's a significant step towards further evidence-based practice in hyperbaric therapy, promising to elevate the standard of care.”
Hyperbaric oxygen therapy involves delivering 100% oxygen at increased atmospheric pressure, promoting healing by improving tissue oxygenation, reducing inflammation, and supporting immune function.
This pilot, facilitated by the DataBiologics platform, will empower physicians using MD Hyperbaric’s therapies to track key metrics such as quality of life outcomes. Data collected will provide insight into how HBOT performs in the real-world equipping providers with insights to enhance treatment protocols.
About MD Hyperbaric:
MD Hyperbaric delivers state-of-the-art hyperbaric oxygen therapy tailored to support healing, recovery, and overall wellness. With a focus on chronic disease management and post-surgical recovery, MD Hyperbaric helps patients achieve sustainable improvements in their health through scientifically backed, non-invasive therapies.
About DataBiologics:
DataBiologics empowers healthcare providers with an intuitive platform to study the safety and efficacy of novel treatments in orthopedics and beyond. This real-world patient data will empower providers, patients and industry with insights to support more informed treatment decisions and better patient care.
Learn more about MD Hyperbaric: https://mdhyperbaric.com
Learn more about DataBiologics: https://www.databiologics.com